A Szentágothai János Kutatóközpont a PTE korszerű, nemzetközi tudományszervezési és menedzsment normák szerint kialakított új intézménye, amely az élettudományi, élettelen természettudományi, valamint környezettudományi oktatás...
The most important research topic of our research group is heart failure, which is the only cardiovascular disease with an increasing incidence. Heart failure is a disease characterised by poor prognosis and its mortality has not significantly reduced despite the numerous therapeutic possibilities. We also investigate the therapeutic approaches of other pathologies leading to heart failure, for example/such as myocardial infarction, hypertension and atrial fibrillation.
We are studying the role of the interplay between certain signaling factors and mitochondrial quality control in these pathological progressions. In addition, we are seeking to find possible therapeutic targets along this axis.
Based on research in recent years, the PARP enzyme is one of the most promising targets in both the prevention of heart failure and the treatment of established disease. PARP-inhibitors besides their “orthodox” NAD+-preserving effect, can also influence several signal transduction pathways. They have a direct mitochondrial protective effect, preserve the activity of the components of the respiratory chain, have a positive effect on the activity of signaling factors, thereby reducing the process of cardiovascular connective tissue remodeling.
An other promising path is the pharmacological modulation of the mitochondrial quality control. We are conducting experiments on the inhibition of fission, promoting fusion processes and enhanced the mitochondrial biogenesis, thus uncovering the role of the above mentioned processes on the development of heart failure.
The effect of resveratrol on the cardiovascular system from molecular mechanisms to clinical results. Roland Gal, Laszlo Deres, Kalman Toth, Robert Halmosi, Tamas Habon. Int J Mol Sci. 2021 Sep 21;22(18):10152. doi: 10.3390/ijms221810152.
Modulation of mitochondrial quality control processes by BGP-15 in oxidative stress scenarios: from cell culture to heart failure. Orsolya Horvath, Katalin Ordog, Kitti Bruszt, Nikoletta Kalman, Dominika Kovacs, Balazs Radnai, Ferenc Gallyas, Kalman Toth, Robert Halmosi, Laszlo Deres. Oxid Med Cell Longev. 2021 Feb 27;2021:6643871. doi: 10.1155/2021/6643871.
BGP-15 protects against heart failure by enhanced mitochondrial biogenesis and decreased fibrotic remodelling in spontaneously hypertensive rats. Orsolya Horvath, Katalin Ordog, Kitti Bruszt, Laszlo Deres, Ferenc Gallyas, Balazs Sumegi, Kalman Toth, Robert Halmosi. Oxid Med Cell Longev. 2021 Jan 30;2021:1250858. doi: 10.1155/2021/1250858.
Mitochondrial protective effects of PARP-inhibition in hypertension-induced myocardial remodeling and in stressed cardiomyocytes. Katalin Ordog, Orsolya Horvath, Krisztian Eros, Kitti Bruszt, Szilard Toth, Dominika Kovacs, Nikoletta Kalman, Balazs Radnai, Laszlo Deres, Ferenc Gallyas Jr, Kalman Toth, Robert Halmosi. Life Sci. 2021 Mar 1;268:118936. doi: 10.1016/j.lfs.2020.118936.
Protective effects of the novel amine-oxidase inhibitor multi-target drug SZV 1287 on streptozotocin-induced beta cell damage and diabetic complications in rats. Valéria Tékus, Ádám István Horváth, Kata Csekő, Krisztina Szabadfi, Andrea Kovács-Valasek, Bese Dányádi, László Deres, Róbert Halmosi, Éva Sághy, Zoltán V Varga, Ernest Adeghate, Tamás Kőszegi, Péter Mátyus, Róbert Gábriel, Péter Ferdinandy, Erika Pintér, Zsuzsanna Helyes. Biomed Pharmacother. 2021 Feb;134:111105. doi: 10.1016/j.biopha.2020.111105.
Resveratrol improves heart function by moderating inflammatory processes in patients with systolic heart failure. Roland Gal, Laszlo Deres, Orsolya Horvath, Krisztian Eros, Barbara Sandor, Peter Urban, Szilvia Soos, Zsolt Marton, Balazs Sumegi, Kalman Toth, Tamas Habon, Robert Halmosi. Antioxidants (Basel). 2020 Nov 11;9(11):1108. doi: 10.3390/antiox9111108.
Hemorheological alterations in patients with heart failure with reduced ejection fraction treated by resveratrol. Roland Gal, Dora Praksch, Peter Kenyeres, Miklos Rabai, Kalman Toth, Robert Halmosi, Tamas Habon. Cardiovasc Ther. 2020 Jun 30;2020:7262474. doi: 10.1155/2020/7262474. eCollection 2020.
The effects of bradykinin B1 receptor antagonism on the myocardial and vascular consequences of hypertension in SHR rats. Laszlo Deres, Krisztian Eros, Orsolya Horvath, Noemi Bencze, Csongor Cseko, Sandor Farkas, Tamas Habon, Kalman Toth, Robert Halmosi. Front Physiol. 2019 May 21;10:624. doi: 10.3389/fphys.2019.00624.
Doxycycline protects against ROS-induced mitochondrial fragmentation and ISO-induced heart failure. Adam Riba, Laszlo Deres, Krisztian Eros, Aliz Szabo, Klara Magyar, Balazs Sumegi, Kalman Toth, Robert Halmosi, Eszter Szabados. PLoS One. 2017 Apr 6;12(4):e0175195. doi: 10.1371/journal.pone.0175195.
Chronic PARP-1 inhibition reduces carotid vessel remodeling and oxidative damage of the dorsal hippocampus in spontaneously hypertensive rats. Krisztian Eros, Klara Magyar, Laszlo Deres, Arpad Skazel, Adam Riba, Zoltan Vamos, Tamas Kalai, Ferenc Gallyas Jr, Balazs Sumegi, Kalman Toth, Robert Halmosi. PLoS One. 2017 Mar 24;12(3):e0174401. doi: 10.1371/journal.pone.0174401.
Cardioprotective effect of resveratrol in a postinfarction heart failure model. Adam Riba, Laszlo Deres, Balazs Sumegi, Kalman Toth, Eszter Szabados, Robert Halmosi. Oxid Med Cell Longev. 2017;2017:6819281. doi: 10.1155/2017/6819281.
PARP inhibition and postinfarction myocardial remodeling. Robert Halmosi, Laszlo Deres, Roland Gal, Krisztian Eros, Balazs Sumegi, Kalman Toth. Int J Cardiol. 2016 Aug;217 Suppl:S52-9. doi: 10.1016/j.ijcard.2016.06.223. doi: 10.1016/j.ijcard.2016.06.223
